{
    "paper_id": "3e904b2318a03c87d35a5195e2de9cf677c6db18",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "perforin/granzyme cell death pathway, 7-9 role of assays, 9 ROS/ROI pathway in, 8-9 mechanisms of, 4-9 interaction of Fc receptors and effector cell, 4 in monoclonal antibody therapy of cancer, 9-14 NK-cell-mediated, 5-6, 12 with polymorphonuclear cells (PMN), 12-13 protective role against infectious disease, 14-18, 15t-16t herpes simplex virus (HSV), 17 human and simian immunodeficiency virus, 17 against a vaginal SHIV challenge, 17-18 rational modification of, 18-19 receptors involved in, 3",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Fc, 3t, 9-11 in vitro activity, 10t-11t Antibody-dependent enhancement (ADE), 1, 36-38 contribution of FcR-mediated phenomena, 5 IgG antibodies residual, 5 in protozoan parasites of macrophages, 9-12 two-loop model of, 4f in viruses, 2-9, 3t dengue viruses, 2-8 DENV infections, 6-7 feline enteric coronavirus (FECV), 8-9 feline infectious peritonitis virus (FIPV), 8-9 Anti-cancer mAb mechanisms, 1 Antigen-presenting cells (APCs), 2 Anti-HIV antibodies, 57 Anti-tumor mAbs, 49-51 Auristatin, 2-3 Autoimmune diseases and Fc\u03b3Rs associated with systemic lupus erythematosus (SLE), 7t cell activation, 3 co-expression of activation and inhibition, 2-3 cytokine-mediated changes, 11-12 efferent response, 8-10, 11f Fc\u03b3RIIB regulation by, 7-8 role in efferent response, 8-9 inhibitory signaling pathways, 4-5 disturbances in, 5 ITIM-and SHIP-independent signaling pathway, 4-5 linkage and association studies, 1-2 signaling pathways, 3-4 therapeutic interventions, 12-13 threshold for B-cell activation, 5-7 B Bactericidal permeability increasing (BPI) protein, 4 Basophils, 4 B-cell activating factor (BAFF), 2 B-cell malignancies, 1 B-cell receptor (BCR), 1-2 B cells, 5-7 activated, 2-3 antigen-stimulated, 3 autoreactive, 2 C3b opsonization and, 56-57 development in bone marrow, 1-2 expression of positive and negative co-receptors, 6 Fc\u03b3RIIB regulation of, 6-7 autoantibody production, 7-11 in germinal center (GC), 3-6 regulatory checkpoints during light chain rearrangement, 2 selection, activation, and tolerance in peripheral immune system, 2-3 self-reactive, 2",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Bispecific T-cell engagers ( , [7] [8] 8t MacFc\u03b3RI, 7, 9 MacFc\u03b3RII, 10 MacFc\u03b3RIIB, [7] [8] 8, [10] [11] [7] [8] Macrophages, 1-2, 3t, 12-13, 29 activation of, 9-10 blood-resident, 1-2 killing of pathogens, 10 tissue specialization in, 1-2 MCMV infection, 83-84 Membrane attack complex (MAC), 49-51, 63-64 role in inducing cell destruction/ tissue injury, 63-64 MHC-peptide complexes, 13 MoFc\u03b3RIIB, 4-5 MoFc\u03b3RIV, 5 Mogamulizumab, 3-4 Monoclonal antibodies, 9-11. See also Therapeutic monoclonal antibodies (mAbs) anti-HER2, 3 in cancer therapy, 11-14 Fc region of, 12-13 interacting mechanisms, 7 mechanism of action animal models, 3-4 antibody-dependent cellular cytotoxicity, 7 clinical trials and correlative assays, 4-6 complement fixation, 6-7 individual, 6-7 signaling, 6 in vitro analysis, 1-3 structure, 12f therapeutic payloads of, T T FH cells, 5 T follicular helper cells, 2-3 Therapeutic monoclonal antibodies (mAbs), 3 Fc-mediated effector functions clinical data, 5-6 for immunotherapy, 4-5 preclinical data, 4-5 strategies to improve, 12-13 mechanism of action, 1, 2f in treatment of cancer, 1-4, 3f Toll-like receptors (TLRs), 5 Toxoplasma gondii, 38-39 Trastuzumab, 1-2, 4-7, 11-14, 21 Trastuzumab emtansine (T-DM1), 21 TRIM21 protein, 36 Trogocytosis, 55 V V158 allele, 8-9 V-gene, 3-4 X XmAb5574, 12-13 Y Yersinia effector proteins, 34",
            "cite_spans": [
                {
                    "start": 29,
                    "end": 30,
                    "text": ",",
                    "ref_id": null
                },
                {
                    "start": 31,
                    "end": 34,
                    "text": "[7]",
                    "ref_id": null
                },
                {
                    "start": 35,
                    "end": 38,
                    "text": "[8]",
                    "ref_id": null
                },
                {
                    "start": 39,
                    "end": 51,
                    "text": "8t MacFc\u03b3RI,",
                    "ref_id": null
                },
                {
                    "start": 52,
                    "end": 54,
                    "text": "7,",
                    "ref_id": null
                },
                {
                    "start": 55,
                    "end": 67,
                    "text": "9 MacFc\u03b3RII,",
                    "ref_id": null
                },
                {
                    "start": 68,
                    "end": 82,
                    "text": "10 MacFc\u03b3RIIB,",
                    "ref_id": null
                },
                {
                    "start": 83,
                    "end": 86,
                    "text": "[7]",
                    "ref_id": null
                },
                {
                    "start": 87,
                    "end": 90,
                    "text": "[8]",
                    "ref_id": null
                },
                {
                    "start": 91,
                    "end": 93,
                    "text": "8,",
                    "ref_id": null
                },
                {
                    "start": 94,
                    "end": 98,
                    "text": "[10]",
                    "ref_id": null
                },
                {
                    "start": 99,
                    "end": 103,
                    "text": "[11]",
                    "ref_id": null
                },
                {
                    "start": 104,
                    "end": 107,
                    "text": "[7]",
                    "ref_id": null
                },
                {
                    "start": 108,
                    "end": 111,
                    "text": "[8]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Hypobromous acid (HOBr",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Hypochlorous acid (HOCl",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Hypoiodous acid (HOI",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF1": {
            "text": "Phosphorylethanolamine (PE), 10 Plasmacytoid DCs, 1-2 Platelet-activating factor (PAF), 4 Programmed cell death (PCD), 2 Radioimmunotherapies (RITs), 21 Rituximab, 1, 4-6, 10-13, 62-63 Staphylococcus aureus (SpA) protein, 2 Streptococcus pyogenes, 35 Streptopain (SpeB), 35",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}